Matrix metalloproteinase inhibitors: A review

BioDrugs

Volumn 9, Issue 4, 1998, Pages 325-335

  Watson, Susan A ^a   Tierney, Gill ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; BATIMASTAT; BE 16627B; CDP 845; CIPEMASTAT; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DOXYCYCLINE; HYDROXAMIC ACID; ILOMASTAT; MARIMASTAT; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; MINOCYCLINE; N1 [2,2 DIMETHYL 1 [(METHYLAMINO)CARBONYL]PROPYL] N4 HYDROXY 2 (2 METHYLPROPYL)BUTANEDIAMIDE; SC 44463; TETRACYCLINE; THROMBOCYTE FACTOR 4; TISSUE INHIBITOR OF METALLOPROTEINASE; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; ASCITES CELL; CANCER INHIBITION; CELL GROWTH; CLINICAL TRIAL; EXTRACELLULAR MATRIX; HUMAN; IN VITRO STUDY; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAPLEURAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; METASTASIS; NONHUMAN; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; REVIEW; TUMOR CELL LINE;

EID: 0031970222     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-199809040-00005     Document Type: Review

References (44)

1. Brown PD, Giavazzi R. Matrix metalloproteinase inhibition: a review of anti-tumour activity. Ann Oncol 1995; 6: 967-74
2. Jarvinen M, Rinne A, Hopsu-Havu VK. Human cystatins in normal and diseased tissues - a review. Acta Histochem 1987; 82: 5-18
3. Stetler-Stevenson WG, Krutzsch HC, Liotta LA. Tissue inhibitor of metalloproteinase (TIMP-2). J Biol Chem 1989; 264 (29): 17374-8
4. Johnson WH, Roberts NA, Borkakoti NJ. Collagenase inhibitors their design and potential therapeutic use. Enzyme Inhibition 1987; 2: 1-22
5. Bode W, Reinemer P, Huber R, et al. The X-ray crystal structure of a catalytic domain of human neutrophil collagenase inhibited by a substrate analogue reveals the essentials for catalysis and specificity. EMBO J 1994; 13: 1263-9
6. Lee W, Aiken K, Kulkarni G, et al. Collagenase activity in recurrent periodontitis: relationship to disease progression and doxycycline therapy. J Periodont Res 1991; 26: 470-85
7. Golub L, Ramamurthy NS, MacNamara TF, et al. Tetracyclines inhibit connective tissue breakdown: new therapeutic implications for an old family of drugs. Crit Rev Oral Biol Med 1991; 2: 297-322
8. Vincenti MP, Clark IM, Brinkerhoff CE. Using inhibitors of metalloproteinases to treat arthritis. Easier said than done? Arthritis Rheum 1994; 37: 1115-26
9. Karakiulakis G, Missirlis E, Maragoudakis ME. Basement membrane collagen-degrading activity from a malignant tumour is inhibited by anthracycline antibiotics. Biochim Biophys Acta 1990; 1035: 218-22
10. Galardy RE, Grobelny D, Foellmer HG, et al. Inhibition of angiogenesis by the matrix metalloproteinase inhibitor N-(2R-2-(hydroxamidocarbonymethyl)-4-methylpentanoyl-L-tryptophan methylamide. Cancer Res 1994; 54: 4715-8
11. Chirivi RGS, Garofalo A, Crimmin MJ, et al. Inhibition of the metastatic spread and growth of B16-BL6 murine melanoma by a synthetic matrix metalloproteinase inhibitor. Int J Cancer 1994; 58: 460-4
12. Davies B, Brown P, East N, et al. A synthetic matrix metalloproteinase inhibitor decreases tumour burden and prolongs survival of mice bearing human ovarian carcinoma xenografts. Cancer Res 1993; 53: 2087-91
13. Sledge Jr GW, Qulali M, Goulet R, et al. Effect of matrix metalloproteinase inhibitor batimastat on breast cancer re-growth and metastasis in athymic mice. J Natl Cancer Inst 1995; 87: 293-8
14. Taraboletti G, Garofalo A, Belotti D, et al. Inhibition of angiogenesis and murine hemangioma growth by batimastat, a synthetic inhibitor of matrix metalloproteinases. J Natl Cancer Inst 1995; 87: 293-8
15. Watson SA, Morris TM, Robinson G, et al. Inhibition of organ invasion by the matrix metalloproteinase inhibitor batimastat (BB-94) in two human colon carcinoma metastasis models. Cancer Res 1995; 55: 3629-33
16. Eccles SA, Box GM, Court WJ, et al. Control of lymphatic and hematogenons metastasis of a rat mammary carcinoma by the matrix metalloproteinase inhibitor batimastat (BB-94). Cancer Res 1996; 56: 2815-22
17. Watson SA, Morris TM, Parsons SL, et al. Therapeutic effect of the matrix metalloproteinase inhibitor, batimastat, in a human colorectal cancer ascites model. Br J Cancer 1996; 74: 1354-8
18. Zubair AC, Ali SA, Rees RC, et al. The effect of BB-94 (batimastat) on the in vivo behaviour of human lymphoma cells in SCID mice [abstract]. Br J Cancer 1996; 73 Suppl. 26: 42
19. Reich R, Thompson EW, Iwamoto Y, et al. Effects of inhibitors of plasminogen activator, serine proteinases, and collagenase IV on the invasion of basement membranes by metastatic cells. Cancer Res 1988; 48: 3307-12
20. Wang X, Fu X, Brown PD, et al. Matrix metalloproteinase inhibitor BB-94 (batimastat) inhibits human colon tumour growth and spread in a patient-like orthotopic model in nude mice. Cancer Res 1994; 54: 4726-8
21. Mignatti P, Robbins E, Rifkin DB. Tumour invasion through the human anmiotic membrane: requirement for a proteinase cascade. Cell 1996; 47: 487-98
22. DeClerck YA, Yean DT, Chan D, et al. Inhibition of tumour invasion of smooth muscle cell layers by recombinant human metalloproteinase inhibitor (rMI/rTIMP-2). Cancer Res 1991; 51: 2151-7
23. Schultz RM, Silberman S, Persky B, et al. Inhibition by human recombinant tissue inhibitor of metalloproteinases of human amnion invasion and lung colonisation by murine B16-F10 melanoma cells. Cancer Res 1988; 48: 5539-45
24. Khokha R, Zimmer MJ, Wilson SM, et al. Up-regulation of TIMP-1 expression in B16-F10 melanoma cells suppresses then metastatic ability in chick embryo. Clin Exp Metastasis 1992; 10: 365-70
25. Khokha R. Suppression of the tumourigenic and metastatic abilities of murine B16-F10 melanoma cells in vivo by overexpression of the tissue inhibitor of metalloproteinases-1. J Natl Cancer Inst 1994; 86: 299-304
26. Koop S, Khokha R, Schmidt EE, et al. Overexpression of metalloproteinase inhibitor in B16-F10 cells does not affect extravasation but reduces tumour growth. Cancer Res 1994; 54: 4791-7
27. Watanabe M, Takahashi Y, Ohta T, et al. Inhibition of metastasis in human gastric cancer cells transfected with tissue inhibitor of metalloproteinase-1 gene in nude mice. Cancer Suppl 1996; 77 (8): 1676-80
28. Declerck YA, Perez N, Shimada H, et al. Inhibition of invasion and metastasis in cells transfected with an inhibitor of metalloproteinases. Cancer Res 1992; 52: 701-8
29. Montgomery AMP, Mueller BM, Reisfeld RA, et al. Effect of tissue inhibitor of the matrix metalloproteinases-2 expression on the growth and spontaneous metastasis of a human melanoma cell line. Cancer Res 1994; 54: 5467-73
30. Richards CD, Shoyab M, Brown TJ, et al. Selective regulation of metalloproteinase inhibitor (TIMP-1) by oncostatin M in fibroblasts in culture. J Immunol 1993; 150: 5596-603
31. Liu L, Hudgins WR, Shack S, et al. A natural product with potential use in cancer intervention. Int J Cancer 1995; 62: 345-50
32. Chander SK, Antoniw P, Beeley NR, et al. An in vivo model for screening peptidomimetic inhibitors of gelatinase A. J Pharm Sci 1995; 84: 404-9
33. Naito K, Kanbayashi N, Nakajima S, et al. Inhibition of growth of human tumour cells in nude mice by a metalloproteinase inhibitor. Int J Cancer 1994; 58: 730-5
34. Tamargo RJ, Bok RA, Brem H. Angiogenesis inhibition by minocycline. Cancer Res 1991; 51: 672-5
35. Zucker MB, Katz IR. Platelet factor 4: production, structure and physiologic and immunologic action. Proc Soc Exp Biol Med 1991; 198: 693-702
36. Maione TE, Gray GS, Petro J, et al. Inhibition of angiogenesis by recombinant human platelet factor-4 and related peptides. Science 1990; 237: 77-9
37. Sharpe RJ, Randolph HR, Scott CF, et al. Growth inhibition of murine melanoma and human colon carcinoma by recombinant human platelet factor-4. J Natl Cancer Inst 1990; 82: 848-53
38. Kolber DL, Knisely TL, Maione TE. Inhibition of development of murine melanoma lung metastases by systematic administration of recombinant human platelet factor-4. J Natl Cancer Inst 1995; 87: 304-8
39. Nicoletti MI, Garofalo A, Lucchini V, et al. Batimastat potentiates cisplatin activity on human ovarian carcinoma xenografts [abstract]. Eur J Cancer 1996; 32A Suppl. 1: 6
40. Watson SA, Morris TM, Parsons S, et al. Combined therapeutic effect of marimastat and cisplatin on the in vivo growth of a human small cell lung cancer [abstract]. Br J Cancer 1996; 73 Suppl. 26: 29
41. Anderson IC, Shipp MA, Docherty AJP, et al. Combination therapy including a gelatinase inhibitor and cytotoxic agent reduces local invasion and metastasis of murine Lewis lung carcinoma. Cancer Res 1996; 56: 715-8
42. Macaulay V, O'Byrne K, Saunders M, et al. Phase I study of the matrix metalloproteinase inhibitor batimastat (BB-94) in patients with pleural effusions [abstract]. Br J Cancer 1995; 71 Suppl. 24: 11
43. Beattie GJ, Young HA, Smyth JF. Phase 1 study of intraperitoneal metalloproteinase inhibitor BB-94 in patients with malignant ascites [abstract]. 8th NCI-EORTC Symposium of New Drugs in Cancer Therapy. 1994 Mar 15-18: Amsterdam
44. de Takats PG, Young A, Kiernan J, et al. Phase I study of oral batimastat in patients with metastatic bone disease [abstract]. Br J Cancer 1996; 73 Suppl. 26: 51